MARKET

SVA

SVA

Sinovac Biotech Ltd
NASDAQ
6.47
0.00
0.00%
Suspension 16:00 10/19 EDT
OPEN
6.47
PREV CLOSE
6.47
HIGH
6.47
LOW
6.47
VOLUME
0
TURNOVER
--
52 WEEK HIGH
6.58
52 WEEK LOW
6.25
MARKET CAP
643.78M
P/E (TTM)
0.0872
1D
5D
1M
3M
1Y
5Y
BRIEF-Oci International Says Investment Fund Was Set Up
Reuters · 3d ago
Jim Cramer Says China's Vaccines 'Don't Work' But Xi Won't Admit It
Benzinga · 5d ago
Chinese and Indonesian presidents pledge more COVID vaccine cooperation
Reuters · 11/16 20:17
Sinovac Biotech Says World Health Organization Approved Varicella Vaccine
Sinovac Biotech Says World Health Organization Approved Varicella Vaccine
MT Newswires · 11/04 05:25
Reported Late Thursday, Sinovac Biotech's Varicella Vaccine Prequalified By WHO
Benzinga · 11/04 04:58
BRIEF-Sinovac Biotech Says Varicella Vaccine Prequalified By WHO
Reuters · 11/04 02:04
SINOVAC Varicella Vaccine Prequalified by WHO
BEIJING, November 04, 2022--Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that it received prequalification from the World Health Organization (WHO) for its live ...
Business Wire · 11/04 02:03
SINOVAC to Showcase Products at CPHI Frankfurt
BEIJING, October 28, 2022--Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the world’s largest pharmaceutical ...
Business Wire · 10/28 09:00
More
About SVA
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Webull offers kinds of Sinovac Biotech Ltd. stock information, including NASDAQ:SVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SVA stock methods without spending real money on the virtual paper trading platform.